Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one

The systemic treatments for drug reaction with eosinophilia and systemic symptoms (DRESS) beyond corticosteroids.

Journal Selection Sample Work

Choosing the right journal is essential to maximize the visibility, credibility, and clinical impact of academic work. This journal selection report evaluates appropriate peer-reviewed outlets for the manuscript titled “The Systemic Treatments for Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Beyond Corticosteroids.” The shortlisted journals—Journal of the American Academy of Dermatology, The Journal of Allergy and Clinical Immunology, and Clinical Pharmacology & Therapeutics—were selected based on their focus on severe drug reactions, immunologic mechanisms, and advanced systemic therapies. Considerations included scope relevance, readership, indexing, impact, and contribution to dermatology, allergy, and pharmacology practice.

A review of steroid-sparing DRESS therapy that sits between three disciplines

Drug reaction with eosinophilia and systemic symptoms (DRESS), also described as drug-induced hypersensitivity syndrome, is a severe, delayed, T-cell–mediated reaction to medication. It typically combines a widespread rash with fever, eosinophilia and involvement of internal organs, and it can relapse or persist for weeks. Systemic corticosteroids remain the usual first-line treatment, but prolonged courses carry their own harms and some patients respond poorly, which is why steroid-sparing options such as cyclosporine and biologics that target the interleukin-5 pathway attract growing interest.

The manuscript behind this sample, The systemic treatments for drug reaction with eosinophilia and systemic symptoms (DRESS) beyond corticosteroids, is therefore hard to place. A dermatologist sees DRESS as a severe cutaneous adverse reaction, an immunologist sees a hypersensitivity syndrome driven by immune dysregulation, and a clinical pharmacologist sees an adverse drug reaction that needs careful risk–benefit judgement. The journal selection report is written to resolve that ambiguity: it recommends one leading journal from each of these three communities and explains what each would expect from the paper.

Starting from the author's keywords

The report opens with a short job sheet: manuscript title, date and the author preferences, expressed here as five keywords — corticosteroid; cyclosporine; drug reaction with eosinophilia and systemic symptoms; drug-induced hypersensitivity syndrome; and IL-5/IL-5R inhibitors. A comment line confirms that every recommended journal has regularly published articles in the author's area. Anchoring the search to the keywords matters because the same review could be framed in quite different ways, and the keywords show that the author's emphasis is on therapy, not on diagnosis or epidemiology.

How dermatology, allergy and pharmacology journals were matched to the manuscript

Each of the three recommendations follows the same two-part pattern. First comes a paragraph on why the journal suits the topic; second comes evidence that it has already published on related subjects, with full references and DOIs.

  • Journal of the American Academy of Dermatology (Elsevier) is presented as the dermatology-led option, suited to a review written from the perspective of clinical management and outcomes in dermatologic emergencies. Its supporting examples include a 2013 two-part clinical review of DRESS syndrome and a review of toxic epidermal necrolysis.
  • The Journal of Allergy and Clinical Immunology (Elsevier) is framed around immunopathogenesis. Because DRESS is a T-cell–mediated hypersensitivity syndrome, the report argues that a paper discussing steroid-sparing agents, biologics and cytokine-directed treatment would fit the journal's interest in mechanism-driven therapy.
  • Clinical Pharmacology & Therapeutics (Wiley-Blackwell) is recommended for an angle centred on pharmacological mechanisms, safety and individualised treatment strategies.

A later section, "Supporting Information – Rationale for Inclusion and Scope", restates each journal's rationale and scope in a compact two-row table, so an author can check fit at a glance without rereading the longer narrative.

What the journal comparator table puts side by side

The comparator gathers the practical parameters into one grid. The figures below are as reported in the sample; impact factors, charges and editorial statistics change from year to year and should be rechecked on each journal's website before submission.

ParameterJAADJACIClin Pharmacol Ther
Impact factor (as reported)11.811.26.3
Review duration (as reported)4–8 weeksabout 0.9–1 month, first roundabout 6 weeks, first round
APC (as reported)USD 4,500USD 5,200USD 4,630
Word limit2,5003,5004,000
Figures/tables587

The grid also lists indexing (MEDLINE/PubMed for all three, with Scopus, Web of Science and other services named), the society each journal speaks for (the American Academy of Dermatology; the American Academy of Allergy, Asthma and Immunology; and the American Society for Clinical Pharmacology and Therapeutics) and approximate rejection and acceptance rates. The length limits deserve particular attention: a 2,500-word ceiling and a maximum of five display items would force a much tighter review than a 4,000-word allowance with up to 50 references.

Turning the comparison into a submission decision

The report does not rank the journals; it leaves the author to weigh trade-offs. A practical reading might be: choose the dermatology journal if the paper is written for clinicians managing the acute rash and organ involvement; choose the allergy and immunology journal if the strongest material concerns cytokine pathways and IL-5 blockade; choose the pharmacology journal if the review compares agents, dosing and safety in depth. Whichever is chosen, the manuscript will need reshaping to that journal's article type, word count and reference style, which is where manuscript formatting becomes part of the plan.

An appendix of five questions closes the document, covering suitability, readership, review speed, indexing and academic reach. It is written so that co-authors who did not commission the report can follow the reasoning. Authors who want this kind of shortlist for their own work can request it through Pubrica's journal selection service, and the chosen target can then be carried forward into journal submission support.

Questions about this sample

Why does the DRESS report recommend journals from three different specialties?

DRESS is at once a severe skin reaction, an immune-mediated hypersensitivity syndrome and an adverse drug reaction. A review of steroid-sparing treatment could therefore be written for dermatologists, immunologists or clinical pharmacologists. Recommending one leading journal from each field lets the author decide which audience the paper is really written for and adjust the framing to match.

Which treatments does the manuscript focus on, according to the report?

The author keywords listed in the report are corticosteroid, cyclosporine, drug reaction with eosinophilia and systemic symptoms, drug-induced hypersensitivity syndrome, and IL-5/IL-5R inhibitors. This indicates a therapy-focused review that looks at options beyond systemic corticosteroids, including immunosuppressants and biologics that target the interleukin-5 pathway.

Are the impact factors and charges in the sample still current?

Not necessarily. The impact factors of 11.8, 11.2 and 6.3, and the article processing charges between USD 4,500 and USD 5,200, are as reported in the sample at the time it was prepared. These metrics are updated every year, so any author using the report as a model should confirm current figures on each journal's own website.

How should an author use the word and figure limits in the comparator?

They show how much the manuscript would need to change for each target. The sample lists a 2,500-word limit with five figures or tables for the dermatology journal, against 4,000 words and seven display items for the pharmacology journal. Checking these limits early prevents a review being drafted at a length the first-choice journal cannot accept.

pubrica services with experts

Research your Services with our experts

Delivered on-time or your money back

Give yourself the academic edge today

Each order includes

  • On-time delivery or your money back
  • A fully qualified writer in your subject
  • In-depth proofreading by our Quality Control Team
  • 100% confidentiality, the work is never re-sold or published
  • Standard 7-day amendment period
  • A paper written to the standard ordered
  • A detailed plagiarism report
  • A comprehensive quality report

Enquire Now

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.